Wells Fargo assumed coverage of Affimed with an Overweight rating and $7 price target, with no changes made to rating or target.
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on AFMD:
- Affimed price target lowered to $1 from $2 at Stifel
- Affimed Reports 2022 Financial Results and Operational Progress
- Affimed to Report Full Year 2022 Financial Results & Corporate Update on March 23, 2023
- Affimed Announces Presentations of Clinical Data from AFM13 Phase 2 REDIRECT and Pre-clinical Data Demonstrating CD16A Shedding Facilitates Repetitive Targeting of Tumor Cells by AFM13-armed NK Cells at the Annual Meeting of the American Association for Cancer Research
- AbCheck Announces Successful Completion of Research and Development Under Grant to Develop a Novel Microfluidics Technology for Functional Antibody Discovery